Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its therapeutic candidates and supply chain quality [5]. Summary by Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Telix Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, are encouraged to contact the firm before January 9, 2026 [2]. Allegations - The complaint alleges that Telix overstated its progress with therapeutic candidates for prostate cancer and inflated the quality of its supply chain [5]. - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [5].
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm